Smoking Research Today is a free monthly online journal that collates and summarizes the latest research about Smoking, including details on cigarettes, cancer, lung, tar, nicotine.

SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease.

Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I

Department of Environmental Medicine, University of Rochester Medical Center, Box 850, 601 Elmwood Avenue, Rochester, NY 14642, USA.

RATIONALE: Abnormal inflammation and accelerated decline in lung function occur in patients with chronic obstructive pulmonary disease (COPD). Human sirtuin (SIRT1), an antiaging and antiinflammatory protein, is a metabolic NAD(+)-dependent protein/histone deacetylase that regulates proinflammatory mediators by deacetylating histone and nonhistone proteins. OBJECTIVES: To determine the expression of SIRT1 in lungs of smokers and patients with COPD, and to elucidate the regulation of SIRT1 in response to cigarette smoke in macrophages, and its impact on nuclear factor (NF)-kappaB regulation. METHODS: SIRT1 and NF-kappaB levels were assessed in lung samples of nonsmokers, smokers, and patients with COPD. Human monocyte-macrophage cells (MonoMac6) were treated with cigarette smoke extract (CSE) to determine the mechanism of CSE-mediated regulation of SIRT1 and its involvement in RelA/p65 regulation and IL-8 release. MEASUREMENTS AND MAIN RESULTS: Peripheral lungs of smokers and patients with COPD showed decreased levels of nuclear SIRT1, as compared with nonsmokers, associated with its post-translational modifications (formation of nitrotyrosine and aldehyde carbonyl adducts). Treatment of MonoMac6 cells with CSE showed decreased levels of SIRT1 associated with increased acetylation of RelA/p65 NF-kappaB. Mutation or knockdown of SIRT1 resulted in increased acetylation of nuclear RelA/p65 and IL-8 release, whereas overexpression of SIRT1 decreased IL-8 release in response to CSE treatment in MonoMac6 cells. CONCLUSIONS: SIRT1 levels were reduced in macrophages and lungs of smokers and patients with COPD due to its post-translational modifications by cigarette smoke-derived reactive components, leading to increased acetylation of RelA/p65. Thus, SIRT1 plays a pivotal role in regulation of NF-kappaB-dependent proinflammatory mediators in lungs of smokers and patients with COPD.

Published 8 April 2008 in Am J Respir Crit Care Med, 177(8): 861-70.
Full-text of this article is available online (may require subscription).

Articles on Smoking published 26 March 2008:

Which forms of child/adolescent externalizing behaviors account for late adolescent risky sexual behavior and substance use?   J Child Psychol Psychiatry, 49(4): 386-94.

BACKGROUND: Health risk behaviors like substance use (alcohol, tobacco, soft/hard drugs) and risky sexual behavior become more prevalent in adolescence. Children with behavior problems are thought to be prone to engage in health risk behaviors later in life. It is, however, unclear which problems within the externalizing spectrum account for these outcomes. METHODS: Three hundred and nine children were followed from age 4/5 years to 18 years (14-year follow-up). Level and course of parent-rated ... [Abstract] [Full-text]

Articles on Smoking published 21 March 2008:

Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.   J Oral Maxillofac Surg, 66(4): 625-31.

PURPOSE: Bisphosphonates (BPs) effectively treat metastatic bone disease, hypercalcemia, and osteoporosis. BP exposure, however, may be associated with osteonecrosis of the jaw (ONJ). The aim of the present study was to estimate the magnitude of the association between intravenous (IV) BP exposure and ONJ, and to identify potential confounders. MATERIALS AND METHODS: Using a case-control study design, the investigators identified and adjudicated a sample of cases with ONJ and matched them ... [Abstract] [Full-text]

Indoor risk factors for cough and their relation to wheeze and sensitization in Chilean young adults.   Am J Public Health, 98(4): 680-6.

OBJECTIVES: We assessed the effects of indoor risk factors, including smoking, on different types of cough and on cough and wheeze in combination. METHODS: Our sample was composed of 1232 men and women residing in a semirural area of Chile. We used a standardized questionnaire, sensitization to 8 allergens, and bronchial hyperresponsiveness to methacholine to assess cough and wheeze characteristics. Information was gathered on dampness, mold, ventilation, heating, housing quality, smoking, and ... [Abstract] [Full-text]

Smoking in moderate/severe preeclampsia worsens pregnancy outcome, but smoking cessation limits the damage.   Hypertension, 51(4): 1042-6.

We studied phenotypic and clinical outcome data in an observational, multicenter cohort study of 1001 Western European white women and their singleton babies, with stringently defined moderate-to-severe preeclampsia. Ninety women admitted to being current smokers; 71 had stopped smoking before entry to the study. Across the categories of never-smoker, stopped, and current smoker there were significant increases in the proportion of women delivering before 34 weeks' gestation (P=0.011), ... [Abstract] [Full-text]

Articles on Smoking published 20 March 2008:

Vaccines to combat smoking.   Expert Opin Biol Ther, 8(4): 379-83.

BACKGROUND: Current US FDA-approved biological therapies for treating smoking target central nervous system processes. Although these therapies have had some success, relapse within a year is still high. Clearly additional strategies are needed to aid individuals in maintaining abstinence. OBJECTIVE/METHODS: We briefly discuss promising research using vaccines to combat smoking and then identify some potentially important directions for future research. RESULTS/CONCLUSIONS: Immunization with a ... [Abstract] [Full-text]

Articles on Smoking published 19 March 2008:

Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.   Clin Pharmacol Ther, 83(4): 531-41.

Understanding the basic and clinical pharmacology of nicotine provides a basis for improved prevention and treatment of tobacco addiction. Nicotine acts on nicotinic cholinergic receptors in the brain to release dopamine and other neurotransmitters that sustain addiction. Neuroadaptation and tolerance involve changes in both nicotinic receptors and neural plasticity. Nicotine addiction can occur in the context of physical dependence characterized by self-medication to modulate negative affect ... [Abstract] [Full-text]

Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers.   Clin Pharmacol Ther, 83(4): 607-14.

Varenicline is an alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist developed as an aid for smoking cessation.This study evaluated varenicline's potential for abuse by smokers (n = 23) and nonsmokers (n = 22). The study used a randomized, double-blind, placebo-controlled, double-dummy crossover design with five treatment periods: 15 and 30 mg amphetamine, 1 and 3 mg varenicline, and placebo. Following each treatment, the participants were assessed on aspects relating to potential ... [Abstract] [Full-text]

Monoamine oxidase inhibition for tobacco pharmacotherapy.   Clin Pharmacol Ther, 83(4): 619-21.

Tobacco addiction is the most significant preventable cause of morbidity and mortality in the Western world, with >430,000 deaths annually from tobacco-related diseases being reported in the United States. Although effective treatments are available for cessation of smoking (e.g., nicotine replacement therapies, sustained-release bupropion and varenicline), they do not work for all smokers. Therefore the development of more effective medications for treating tobacco dependence, based on ... [Abstract] [Full-text]

© 2006-2008 Smoking Research Today. All Rights Reserved.